Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.

Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.

Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days after the companies disclosed that all regulatory conditions to close the deal were fulfilled.

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission clearance.

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.